Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacteria, a genus of probiotic bacteria commonly found in the human gut, have been studied for their potential role in modulating immune function and, by extension, their possible therapeutic benefit in autoimmune disorders. Several preclinical studies and a modest number of clinical trials suggest that supplementation with certain Bifidobacteria strains may help regulate immune responses, lower inflammation, and promote tolerance—mechanisms relevant to autoimmune conditions such as inflammatory bowel disease (IBD), multiple sclerosis, and rheumatoid arthritis.

Evidence supporting these effects is largely based on animal studies and a handful of small-scale human trials, often using multi-strain probiotic formulations (which include Bifidobacteria alongside other bacteria like Lactobacillus). These studies have observed improvements in inflammatory markers and some symptoms. However, results are inconsistent and strain-specific; not all Bifidobacteria have the same effects, and studies rarely focus on "unspecified" strains. Moreover, robust, large-scale randomized controlled trials (RCTs) in humans with well-defined autoimmune diseases are lacking.

Thus, while there is a scientific rationale and some early evidence for the use of Bifidobacteria in supporting autoimmune disorders, the overall quality and quantity of evidence is limited (rating: 2/5). Additional research is needed to clarify which strains are effective, optimal dosages, and which autoimmune conditions may benefit most from such interventions.

More about Bifidobacteria (unspecified)
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by Bifidobacteria (unspecified)

Products containing Bifidobacteria (unspecified)